The earnings surpassed analyst expectations with an adjusted earnings per share (EPS) of $1.19, beating estimates of $0.91 by ...

CVS Health (NYSE:CVS – Free Report) had its price target lifted by JPMorgan Chase & Co. from $80.00 to $81.00 in a report ...

Shareholders will be ecstatic, with their stake up 22% over the past week following CVS Health Corporation's (NYSE:CVS) ...

Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

CVS Health posted Q4 sales of $97.71B, with a 23.3% rise in Health Care Benefits revenue. Fiscal 2025 adjusted EPS guidance ...

CEO David Joyner highlighted the company's Q4 adjusted EPS of $1.19 and adjusted operating income of $2.7 billion. He introduced 2025 adjusted EPS guidance of $5.75 to $6.00, emphasizing recovery in ...

Sees FY25 free cash flow $6.5B. The company said, “The Company issued its full-year 2025 GAAP diluted EPS guidance range of $4.58 to $4.83 and ...

Leerink Partnrs upgraded shares of CVS Health (NYSE:CVS – Free Report) from a hold rating to a strong-buy rating in a ...

CVS Health's adjusted EPS beat estimates at $1.19, surpassing the expected $0.91. Revenue increased to $97.7 billion, exceeding expectations and reflecting a growth of 4.2% year-over-year.

Q4 2024 Earnings Call Transcript February 12, 2025 CVS Health Corporation beats earnings expectations. Reported EPS is $1.19, ...

Retail pharmacy chain CVS Health (CVS) is scheduled to announce its results for the fourth quarter of 2024 before the market ...